Patent Assignment
Reel/Frame 053787/0138
Change of Name
Recorded: 2020-09-16
Pages: 9
Assignor
INTEGRAL EARLY DISCOVERY, INC.
Executed: 2020-09-11
Assignee
VALO EARLY DISCOVERY, INC.
399 BOYLSTON STREET, BOSTON, MASSACHUSETTS, 02116
Covered Properties
(181)
Kinase Inhibitors
PCT:
PCT/US2007/013299 ↗
Novel Compounds and Compositions for the Inhibition of Nampt
PCT:
PCT/US2011/050301 ↗
Novel Compounds and Compositions for the Inhibition of Nampt
PCT:
PCT/US2011/050303 ↗
Novel Compounds and Compositions for the Inhibition of Nampt
PCT:
PCT/US2011/050320 ↗
Novel Compounds and Compositions for the Inhibition of Nampt
PCT:
PCT/US2011/050321 ↗
Novel Compounds and Compositions for the Inhibition of Nampt
PCT:
PCT/US2011/050323 ↗
Amido-Benzyl Sulfoxide Derivatives
PCT:
PCT/US2013/028527 ↗
Alkyl-And Di-Substituted Amido-Benzyl Sulfonamide Derivatives
PCT:
PCT/US2013/028566 ↗
Pyrrolotriazinones and Imidazotriazinones as Ubiquitin-Specific Protease 7 Inhibitors
PCT:
PCT/US2015/067781 ↗
Pyrrolo and Pyrazolopyrimidines as Ubiquitin-Specific Protease 7 Inhibitors
PCT:
PCT/US2015/067831 ↗
3-Aryl-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
PCT:
PCT/US2016/016194 ↗
3-Alkyl Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
PCT:
PCT/US2016/016197 ↗
3-Aryl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
PCT:
PCT/US2016/016200 ↗
3-Alkyl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hda Inhibitors
PCT:
PCT/US2016/016201 ↗
Bicyclic [4,6,0] Hydroxamic Acids as HDAC6 Inhibitors
PCT:
PCT/US2016/016204 ↗
Quinazolinones and Azaquinazolinones as Ubiquitin-Specific Protease 7 Inhibitors
PCT:
PCT/US2016/016542 ↗
Thienopyrimidinones as Ubiquitin-Specific Protease 7 Inhibitors
PCT:
PCT/US2016/016548 ↗
Isothiazolopyrimidinones, Pyrazolopyrimidinones, and Pyrrolopyrimidinones as Ubiquitin-Specific Protease 7 Inhibitors
PCT:
PCT/US2016/016556 ↗
Alpha-Cinnamide Compounds and Compositions as HDAC8 Inhibitors
PCT:
PCT/US2016/022029 ↗
3-Spirocyclic-6-Hydroxamic Acid Tetralins as Hdac Inhibitors
PCT:
PCT/US2016/027755 ↗
3-Spiro-7-Hydroxamic Acid Tetralins as Hdac Inhibitors
PCT:
PCT/US2016/027842 ↗
[6,6] Fused Bicyclic HDAC8 Inhibitors
PCT:
PCT/US2016/050152 ↗
Thienopyridine Carboxamides as Ubiquitin-Specific Protease Inhibitors
PCT:
PCT/US2017/017690 ↗
Thienopyrazine Carboxamides as Ubiquitin-Specific Protease Inhibitors
PCT:
PCT/US2017/017691 ↗
2-Spiro-5- and 6-Hydroxamic Acid Indanes as Hdac Inhibitors
PCT:
PCT/US2017/037970 ↗
Methods Using HDAC11 Inhibitors
PCT:
PCT/US2017/057715 ↗
Carboxamides as Ubiquitin-Specific Protease Inhibitors
PCT:
PCT/US2018/046061 ↗
Isoindolines as Hdac Inhibitors
PCT:
PCT/US2019/028026 ↗
Carboxamides as Ubiquitin-Specific Protease Inhibitors
PCT:
PCT/US2019/045732 ↗
Inhibiting Deubiquitinase USP25 and USP28
PCT:
PCT/US2019/045734 ↗
Derivatives of Squaric Acid with Anti-Proliferative Activity
Pyrido [2,3-D] Pyrimidines and Their Use as Kinase Inhibitors
Improved Raf Inhibitors
Application:
12/988,837 →
Raf Inhibitors
Novel Compounds and Compositions for the Inhibition of Nampt
Novel Compounds and Compositions for the Inhibition of Nampt
Application:
13/820,496 →
Publication:
US 2013/0273034
Novel Compounds and Compositions for the Inhibition of Nampt
Application:
13/820,497 →
Publication:
US 2014/0294805
Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors
Application:
13/949,495 →
Publication:
US 2014/0163003
Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors
Application:
13/949,508 →
Publication:
US 2014/0163004
Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors
Application:
13/949,666 →
Publication:
US 2014/0163005
Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors
Application:
13/949,690 →
Publication:
US 2014/0163006
Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors
Application:
13/949,712 →
Publication:
US 2014/0163222
Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors
Application:
13/949,728 →
Publication:
US 2014/0163223
Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors
Application:
13/949,743 →
Publication:
US 2014/0163007
Novel Compounds and Compositions for the Inhibition of Nampt
Piperidine Derivatives and Compositions for the Inhibition of Nicotinamide Phosphoribosyltransferase (Nampt)
Pyridinyl and Pyrimidinyl Sulfoxide and Sulfone Derivatives
Amido-Benzyl Sulfone and Sulfoxide Derivatives
Amido Spirocyclic Amide and Sulfonamide Derivatives
Pyrrolo and Pyrazolopyrimidines as Ubiquitin-Specific Protease 7 Inhibitors
Pyrrolotriazinones and Imidazotriazinones as Ubiquitin-Specific Protease 7 Inhibitors
Bicyclic [4,6,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
Thienopyrimidinones as Ubiquitin-Specific Protease 7 Inhibitors
Isothiazolopyrimidinones, Pyrazolopyrimidinones, and Pyrrolopyrimidinones as Ubiquitin-Specific Protease 7 Inhibitors
Quinazolinones and Azaquinazolinones as Ubiquitin-Specific Protease 7 Inhibitors
Alpha-Cinnamide Compounds and Compositions as HDAC8 Inhibitors
3-Spirocyclic-6-Hydroxamic Acid Tetralins as Hdac Inhibitors
3-Spiro-7-Hydroxamic Acid Tetralins as Hdac Inhibitors
Pyridinyl and Pyrimidinyl Sulfoxide and Sulfone Derivatives
Application:
15/243,289 →
Publication:
US 2016/0355514
[6,6] Fused Bicyclic HDAC8 Inhibitors
Novel Compounds and Compositions for the Inhibition of Nampt
Piperidine Derivatives And Compositions For the Inhibition Of Nicotinamide Phosphoribosyltransferase (NAMPT)
Application:
15/419,727 →
Publication:
US 2017/0137441
Amido Spirocyclic Amide and Sulfonamide Derivatives
Application:
15/473,110 →
Publication:
US 2017/0216262
Alpha-Cinnamide Compounds and Compositions as HDAC8 Inhibitors
Application:
15/688,732 →
Publication:
US 2018/0044282
Methods Using HDAC11 Inhibitors
Application:
15/789,869 →
Publication:
US 2018/0127386
Quinazolinones and Azaquinazolinones as Ubiquitin-Specific Protease 7 Inhibitors
Pyrrolo and Pyrazolopyrimidines as Ubiquitin-Specific Protease 7 Inhibitors
Isothiazolopyrimidinones, Pyrazolopyrimidinones, and Pyrrolopyrimidinones as Ubiquitin-Specific Protease 7 Inhibitors
Thienopyrimidinones as Ubiquitin-Specific Protease 7 Inhibitors
Alpha-Cinnamide Compounds and Compositions as HDAC8 Inhibitors
Amido Spirocyclic Amide and Sulfonamide Derivatives
Pyrrolotriazinones and Imidazotriazinones as Ubiquitin-Specific Protease 7 Inhibitors
Piperidine Derivatives and Compositions for the Inhibition of Nicotinamide Phosphoribosyltransferase (Nampt)
Application:
16/002,651 →
Publication:
US 2019/0031686
[6,6] Fused Bicyclic HDAC8 Inhibitors
Novel Compounds and Compositions for the Inhibition of Nampt
Thienopyrazine Carboxamides as Ubiquitin-Specific Protease Inhibitors
Thienopyridine Carboxamides as Ubiquitin-Specific Protease Inhibitors
3-Aryl-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
Quinazolinones and Azaquinazolinones as Ubiquitin-Specific Protease 7 Inhibitors
Quinazolinones and Azaquinazolinones as Ubiquitin-Specific Protease 7 Inhibitors
Quinazolinones and Azaquinazolinones as Ubiquitin-Specific Protease 7 Inhibitors
Quinazolinones and Azaquinazolinones as Ubiquitin-Specific Protease 7 Inhibitors
Quinazolinones and Azaquinazolinones as Ubiquitin-Specific Protease 7 Inhibitors
Quinazolinones and Azaquinazolinones as Ubiquitin-Specific Protease 7 Inhibitors
Bicyclic [4,6,0] Hydroxamic Acids as Hdac Inhibitors
Methods Using HDAC11 Inhibitors
Methods Using HDAC11 Inhibitors
Novel Compounds and Compositions for the Inhibition of Nampt
3-Alkyl Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
2-Spiro-5- and 6-Hydroxamic Acid Indanes as Hdac Inhibitors
Alpha-Cinnamide Compounds and Compositions as HDAC8 Inhibitors
Novel Compounds and Compositions for the Inhibition of Nampt
Pyrrolotriazinones and Imidazotriazinones as Ubiquitin-Specific Protease 7 Inhibitors
[6,6] Fused Bicyclic HDAC8 Inhibitors
Thienopyrimidinones as Ubiquitin-Specific Protease 7 Inhibitors
Isothiazolopyrimidinones, Pyrazolopyrimidinones, and Pyrrolopyrimidinones as Ubiquitin-Specific Protease 7 Inhibitors
Pyrrolo and Pyrazolopyrimidines as Ubiquitin-Specific Protease 7 Inhibitors
Bicyclic [4,6,0] Hydroxamic Acids as Hdac Inhibitors
Novel Compounds and Compositions for the Inhibition of Nampt
3-Alkyl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
Carboxamides as Ubiquitin-Specific Protease Inhibitors
Patent:
11,524,966 →
Application:
16/637,692 →
3-Aryl-4-Amido-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Aryl-Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
3-Alkyl Bicyclic [4,5,0] Hydroxamic Acids as Hdac Inhibitors
Methods Using HDAC11 Inhibitors
Alpha-Cinnamide Compounds and Compositions as HDAC8 Inhibitors
Quinazolinones and Azaquinazolinones as Ubiquitin-Specific Protease 7 Inhibitors
2-Spiro-5- and 6-Hydroxamic Acid Indanes as Hdac Inhibitors
Novel Compounds and Compositions for the Inhibition of Nampt
Amido Spirocyclic Amide and Sulfonamide Derivatives
Thienopyrazine Carboxamides as Ubiquitin-Specific Protease Inhibitors
Novel Compounds And Compositions For Inhibition of NAMPT [Amide Sulfonamide]
Application:
61/379,789 →
Novel Compounds And Compositions For Inhibition of NAMPT [AMIDES Sulfones]
Application:
61/379,796 →
Novel Compounds And Compositions For Inhibition of NAMPT [CYANOGUANIDINE SULFONE]
Application:
61/379,800 →
Novel Compounds And Compositions For Inhibition of NAMPT [Urea Sulfonamides]
Application:
61/379,812 →
Novel Compounds And Compositions For Inhibition of NAMPT [Urea Sulfones]
Application:
61/379,819 →
Novel Compounds and Compositions For Inhibition of NAMPT
Application:
61/386,023 →
Novel Compounds And Compositions For Inhibition of NAMPT
Application:
61/386,028 →
Novel Compounds And Compositions For Inhibition of NAMPT
Application:
61/386,033 →
Novel Compounds And Compositions For Inhibition of NAMPT
Application:
61/386,037 →
Novel Compounds And Compositions For Inhibition of NAMPT
Application:
61/386,044 →
Novel Compounds and Compositions for Inhibition of Nampt
Application:
61/475,813 →
Novel Compounds And Compositions For Inhibition of NAMPT
Application:
61/476,590 →
Novel Compounds And Compositions For Inhibition of NAMPT
Application:
61/478,995 →
Novel Compounds And Compositions For Inhibition of NAMPT
Application:
61/480,423 →
Novel Compounds And Compositions For Inhibition of NAMPT
Application:
61/482,537 →
Novel Compounds And Compositions For Inhibition of NAMPT
Application:
61/483,242 →
Novel Compounds And Compositions For Inhibition of NAMPT
Application:
61/483,937 →
Novel Compounds And Compositions For Inhibition of NAMPT
Application:
61/512,546 →
Pyrrolo and Pyrazolopyrimidines as Ubiquitin-Specific Protease 7 Inhibitors
Application:
62/098,141 →
Pyrrolotriazinones and Imidazotriazinones as Ubiquitin-Specific Protease 7 Inhibitors
Application:
62/098,145 →
Bicyclic [4,5,0] Hydroxamic Acids as HDAC6 Inhibitors
Application:
62/110,716 →
Bicyclic [4,6,0] Hydroxamic Acids as HDAC6 Inhibitors
Application:
62/110,719 →
Thienopyrimidinones as Ubiquitin-Specific Protease 7 Inhibitors
Application:
62/112,482 →
Quinazolinones and Azaquinazolinones as Ubiquitin-Specific Protease 7 Inhibitors
Application:
62/112,487 →
Isothiazolopyrimidinones, Pyrazolopyrimidinones, and Pyrrolopyrimidinones as Ubiquitin-Specific Protease 7 Inhibitors
Application:
62/112,540 →
Alpha-Cinnamide Compounds and Compositions as HDAC8 Inhibitors
Application:
62/132,895 →
Spirocyclic Hydroxamic Acids as HDAC6 Inhibitors
Application:
62/149,360 →
Alpha-Cinnamide Compounds and Compositions as HDAC8 Inhibitors
Application:
62/184,335 →
Bicyclic [4,6,0] Hydroxamic Acids as HDAC6 Inhibitors
Application:
62/205,438 →
[6,6] Fused Bicyclic HDAC8 Inhibitors
Application:
62/214,101 →
Alpha-Cinnamide Compounds and Compositions as HDAC8 Inhibitors
Application:
62/270,371 →
2-Spiro-5- and 6-Hydroxamic Acid Indanes as Hdac Inhibitors
Application:
62/351,399 →
Spirocycles as Hdac Inhibitors
Application:
62/410,766 →
Methods of Using HDAC11 Inhibitors
Application:
62/410,767 →
Hdac Inhibitors
Application:
62/410,768 →
Isoindolines as Hdac Inhibitors
Application:
62/660,572 →
Inhibiting Histone Deacetylases
Application:
62/660,581 →
Inhibiting Histone Deacetylases
Application:
62/669,285 →
Isoindolines as Hdac Inhibitors
Application:
62/669,286 →
Ubiquitin-Specific Protease Inhibitors
Application:
62/716,738 →
Ubiquitin-Specific Protease Inhibitors
Application:
62/716,744 →
Ubiquitin-Specific Protease Inhibitors
Application:
62/788,204 →
Ubiquitin-Specific Protease Inhibitors
Application:
62/805,118 →
Inhibiting USP36
Application:
62/840,737 →
Inhibiting OTUB1
Application:
62/840,863 →
Inhibiting Trabid
Application:
62/843,000 →
Inhibiting USP19
Application:
62/843,801 →
Inhibiting Trabid
Application:
62/850,609 →
Inhibiting USP19
Application:
62/857,598 →
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Sep 25, 2007
From: MURTHI, KRISHNA K.; KOSTLER, ROLAND; SMITH, CHASE; BRANDSTETTER, TILMANN
To: GPC BIOTECH AG
Reel/Frame 019878/0970 →
Assignment of Assignor's Interest
Sep 28, 2009
From: GPC BIOTECH AG; GPC BIOTECH, INC.
To: FORMA THERAPEUTICS, INC.
Reel/Frame 023298/0850 →
Assignment of Assignor's Interest
Sep 28, 2009
From: MURTHI, KRISHNA; CASAUBON, REBECCA; KLUGE, ARTHUR F.; SMITH, CHASE
To: GPC BIOTECH, INC.
Reel/Frame 023302/0017 →
Assignment of Assignor's Interest
Sep 28, 2009
From: GPC BIOTECH AG; GPC BIOTECH, INC.
To: FORMA THERAPEUTICS, INC.
Reel/Frame 023301/0352 →
Assignment of Assignor's Interest
Nov 10, 2011
From: YUEN, PO-WAI
To: GENENTECH, INC
Reel/Frame 027210/0175 →
Assignment of Assignor's Interest
Nov 10, 2011
From: BAIR, KENNETH W.; BAUMEISTER, TIMM; BUCKMELTER, ALEXANDRE J.; CLODFELTER, KARL H.
To: FORMA THERAPEUTICS, INC.
Reel/Frame 027210/0124 →
Assignment of Assignor's Interest
Nov 10, 2011
From: BAIR, KENNETH W.; BAUMEISTER, TIMM; BUCKMELTER, ALEXANDRE J.; CLODFELTER, KARL H.
To: FORMA THERAPEUTICS, INC.
Reel/Frame 027210/0311 →
Assignment of Assignor's Interest
Nov 10, 2011
From: DRAGOVICH, PETER; GOSSELIN, FRANCIS; ROTH, BRUCE; YUEN, PO-WAI
To: GENENTECH, INC
Reel/Frame 027210/0237 →
Assignment of Assignor's Interest
Feb 21, 2012
From: FORMA THERAPEUTICS, INC
To: FORMA TM LLC
Reel/Frame 027733/0930 →
Assignment of Assignor's Interest
Jun 19, 2012
From: GPC BIOTECH AG; GPC BIOTECH INC.
To: FORMA THERAPEUTICS, INC.
Reel/Frame 028402/0804 →
Assignment of Assignor's Interest
Jun 19, 2012
From: NEUMAN, LARS; EICKHOFF, JAN; HANNUS, STEFAN; SCHOOP, ANDREAS
To: GPC BIOTECH AG
Reel/Frame 028562/0384 →
Assignment of Assignor's Interest
Jun 19, 2012
From: MURTHI, KRISHNA; CASAUBON, REBECCA; KLUGE, ARTHUR F; SMITH, CHASE C
To: GPC BIOTECH AG; GPC BIOTECH INC
Reel/Frame 028402/0656 →
Assignment of Assignor's Interest
Aug 28, 2013
From: PHARMARON, INC.
To: GENENTECH, INC.
Reel/Frame 031100/0961 →
Assignment of Assignor's Interest
Aug 28, 2013
From: YUEN, PO-WAI
To: PHARMARON BEIJING, CO., LTD
Reel/Frame 031100/0882 →
Assignment of Assignor's Interest
Aug 28, 2013
From: BAIR, KENNETH W.; BAUMEISTER, TIMM R.; BUCKMELTER, ALEXANDRE J.; CLODFELTER, KARL H.
To: FORMA THERAPEUTICS, INC.
Reel/Frame 031102/0180 →
Assignment of Assignor's Interest
Aug 28, 2013
From: GUNZNER-TOSTE, JANET; ZAK, MARK; ZHAO, GUILING
To: GENENTECH, INC.
Reel/Frame 031101/0931 →
Assignment of Assignor's Interest
Aug 28, 2013
From: BAIR, KENNETH W.; BAUMEISTER, TIMM R.; BUCKMELTER, ALEXANRE J.; CLODFELTER, KARL H.
To: FORMA THERAPEUTICS INC.
Reel/Frame 031101/0023 →
Assignment of Assignor's Interest
Aug 28, 2013
From: PHARMARON BEIJING, CO., LTD
To: PHARMARON, INC.
Reel/Frame 031100/0950 →
Assignment of Assignor's Interest
Aug 29, 2013
From: BAIR, KENNETH W.; BAUMEISTER, TIMM R.; ZHENG, XIAOZHANG
To: FORMA THERAPEUTICS, INC.
Reel/Frame 031113/0348 →
Assignment of Assignor's Interest
Aug 29, 2013
From: GOSSELIN, FRANCIS; ZAK, MARK
To: GENENTECH, INC.
Reel/Frame 031113/0341 →
Assignment of Assignor's Interest
Dec 4, 2013
From: FORMA THERAPEUTICS, INC.
To: FORMA TM, LLC
Reel/Frame 031717/0403 →
Assignment of Assignor's Interest
Dec 4, 2013
From: FORMA THERAPEUTICS, INC.
To: FORMA TM, LLC
Reel/Frame 031717/0398 →
Assignment of Assignor's Interest
Jun 13, 2014
From: FORMA THERAPEUTICS, INC.
To: FORMA TM, LLC.
Reel/Frame 033094/0875 →
Assignment of Assignor's Interest
Jan 19, 2016
From: IOANNIDIS, STEPHANOS; TALBOT, ADAM CHARLES; FOLLOWS, BRUCE; BUCKMELTER, ALEXANDRE JOSEPH
To: FORMA THERAPEUTICS, INC.
Reel/Frame 037523/0344 →
Assignment of Assignor's Interest
Jan 19, 2016
From: IOANNIDIS, STEPHANOS; TALBOT, ADAM CHARLES; FOLLOWS, BRUCE; BUCKMELTER, ALEXANDRE JOSEPH
To: FORMA THERAPEUTICS, INC.
Reel/Frame 037523/0395 →